Drug Type ASO |
Synonyms- |
Target |
Mechanism STMN2 modulators(stathmin 2 modulators), TDP43 modulators(TAR DNA binding protein 43 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Central Nervous System Diseases | Preclinical | US | 05 May 2024 |